Company Roche Holding AG Deutsche Boerse AG

Company Roche Holding AG Deutsche Boerse AG

RHO5

CH0012032048

Pharmaceuticals

Analysts' Consensus

Equities

RHO5

CH0012032048

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Roche Holding AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Roche Holding AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Deutsche Boerse AG Other stock markets 09:11:42 28/06/2019 pm IST			5-day change	1st Jan Change
245.6 ^EUR	-0.14%		-.--%	-.--%

29/04	Swiss Equities Close in Red Amid Inflation Spotlight	MT
29/04	Roche Holding AG: slimming down

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Number of employees: 103,605

CHF in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals 76.6 %	48,628	73.2 %	46,279	76.6 %	-4.83%
Diagnostics 23.4 %	17,798	26.8 %	14,162	23.4 %	-20.43%

CHF in Million	2022	Weight	2023	Weight	Delta
United States 46.9 %	29,313	44.1 %	28,352	46.9 %	-3.28%
Rest of Europe 16.1 %	10,328	15.5 %	9,703	16.1 %	-6.05%
Rest of Asia 14.7 %	9,852	14.8 %	8,890	14.7 %	-9.76%
Japan 7.4 %	6,452	9.7 %	4,464	7.4 %	-30.81%
Latin America 4.9 %	2,870	4.3 %	2,971	4.9 %	+3.52%
Germany 4.8 %	3,318	5.0 %	2,893	4.8 %	-12.81%
Africa, Australia and Oceania 2.0 %	1,520	2.3 %	1,212	2.0 %	-20.26%
Switzerland 1.8 %	1,671	2.5 %	1,118	1.8 %	-33.09%
Rest of North America 1.4 %	1,102	1.7 %	838	1.4 %	-23.96%

Managers	Title	Age	Since
Thomas Schinecker CEO	Chief Executive Officer	49	01/03/01
Severin Schwan CHM	Chairman	57	01/08/01
Alan Hippe DFI	Director of Finance/CFO	57	01/11/01
Pascale Schmidt CMP	Compliance Officer	51	01/20/01
Levi Garraway CTO	Chief Tech/Sci/R&D Officer	-	-
Bruno Eschli IRC	Investor Relations Contact	-	-
Silke Hörnstein PRN	Corporate Officer/Principal	49	01/15/01
Annette Luther SEC	Corporate Secretary	54	01/20/01
Claudia Boeckstiegel LAW	General Counsel	60	01/20/01
Cristina A. Wilbur HRO	Human Resources Officer	57	-

Members of the board	Title	Age	Since
Bernard Poussot BRD	Director/Board Member	72	03/15/03
Ulf Mark Schneider BRD	Director/Board Member	59	-
André S. Hoffmann BRD	Director/Board Member	66	01/96/01
Patrick Frost BRD	Director/Board Member	56	17/20/17
Hans Clevers PRN	Corporate Officer/Principal	67	05/19/05
Severin Schwan CHM	Chairman	57	01/08/01
Anita Hauser BRD	Director/Board Member	55	14/17/14
Richard P. Lifton BRD	Director/Board Member	71	03/15/03
Claudia Dyckerhoff BRD	Director/Board Member	58	01/16/01
Joerg Duschmale BRD	Director/Board Member	40	17/20/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	106,691,000	28,989,189 ( 27.17 %)	0	88.91 %
Stock B	1	702,562,700	690,549,764 ( 98.29 %)	12,011,755 ( 1.710 %)

Name	Equities	%	Valuation
ROCHE HOLDING AG 1.434 %	10,073,029	1.434 %	2 569 M €
MFS International (UK) Ltd. 0.5972 %	4,195,654	0.5972 %	1 070 M €
Amundi Asset Management SA (Investment Management) 0.3987 %	2,801,067	0.3987 %	714 M €
Swedbank Robur Fonder AB 0.3107 %	2,182,825	0.3107 %	557 M €
March Asset Management SGIIC SAU 0.2754 %	1,934,990	0.2754 %	493 M €
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0.2340 %	1,644,300	0.2340 %	419 M €
State Street Global Advisors Ltd. 0.2245 %	1,577,032	0.2245 %	402 M €
MFS International Singapore Pte. Ltd. 0.2219 %	1,558,649	0.2219 %	397 M €
CapitalatWork SA 0.1965 %	1,380,872	0.1965 %	352 M €
Swisscanto Fondsleitung AG 0.1907 %	1,339,459	0.1907 %	342 M €

Name	Equities	%	Valuation
MFS Investment Management Canada Ltd. 0.0493 %	2,768,432	0.0493 %	88 M €
Saratoga Research & Investment Management 0.0437 %	2,458,918	0.0437 %	78 M €
Pacer Advisors, Inc. 0.0196 %	1,099,659	0.0196 %	35 M €
NLG Capital, Inc. 0.0129 %	724,880	0.0129 %	23 M €
Van Kampen Asset Management 0.009381 %	527,280	0.009381 %	17 M €
Financial Gravity Asset Management, Inc. 0.009207 %	517,463	0.009207 %	17 M €
MFS International (UK) Ltd. 0.008446 %	474,717	0.008446 %	15 M €
Boston Common Asset Management LLC 0.008147 %	457,875	0.008147 %	15 M €
Truffle Asset Management (Pty) Ltd. 0.004877 %	274,100	0.004877 %	9 M €
Old National Bank (Investment Management) 0.004574 %	257,096	0.004574 %	8 M €

Name	Equities	%	Valuation
Hoffmann Family 64.97 %	69,318,000	64.97 %	18 701 M €
Maja Oeri 7.584 %	8,091,900	7.584 %	2 183 M €
Severin Schwan 0.2294 %	244,786	0.2294 %	66 M €
Rothschild & Co. Bank AG 0.1893 %	202,000	0.1893 %	54 M €
Ignis Investment Services Ltd. 0.1660 %	177,114	0.1660 %	48 M €
Goldman Sachs Advisors BV 0.1574 %	167,973	0.1574 %	45 M €
Pareto Asset Management AS 0.1492 %	159,150	0.1492 %	43 M €
zCapital AG 0.1087 %	116,000	0.1087 %	31 M €
ODDO BHF Trust GmbH 0.0964 %	102,850	0.0964 %	28 M €
State Street Global Advisors Ltd. 0.0541 %	57,737	0.0541 %	16 M €

Name	Equities	%	Valuation
CHUGAI PHARMACEUTICAL CO., LTD 59.89%	1,005,670,000	59.89%	38,367,557,531 $
ROCHE HOLDING AG 1.43%	10,073,029	1.43%	2,568,862,838 $
ENTRADA THERAPEUTICS, INC. 8.17%	2,744,120	8.17%	38,884,180 $
JASPER THERAPEUTICS, INC. 3.02%	454,961	3.02%	13,357,655 $
ALIGOS THERAPEUTICS, INC. 15.19%	11,025,941	15.19%	10,805,422 $
ELOXX PHARMACEUTICALS, INC. 0.06%	1,893	0.06%	1,893 $

Roche Holding AG

Grenzacherstrasse 124

4058, Basel

+41 61 688 11 11

http://www.roche.com

Name	Category and Sector
Sapac Corp. Ltd.
Roche Pharmholding BV Roche Pharmholding BV Medical DistributorsDistribution Services Part of Roche Holding AG, Roche Pharmholding BV is a Dutch company that manufactures and distributes pharmaceutical and vitamin products. The private company is based in Woerden, Netherlands.	Medical Distributors
Roche Finance Europe BV	Finance/Rental/Leasing
Roche Catalyst Investments Ltd.
Roche Financial Investments Ltd.
Roche Intertrade Ltd.
Roche Diagnostics India Pvt Ltd. Roche Diagnostics India Pvt Ltd. Medical SpecialtiesHealth Technology Founded in 1988, Roche Diagnostics India Pvt Ltd. is a subsidiary of Roche Holding AG. The private company is based in Mumbai, India. The Indian company manufactures diagnostic systems and devices for patients, clinicians, and researchers.	Medical Specialties
Viewics India Pvt Ltd.
Roche Financial Management Ltd.
Roche Diagnostics Belgium NV Roche Diagnostics Belgium NV BiotechnologyHealth Technology Part of Roche Holding AG, Roche Diagnostics Belgium NV is a Belgian company that develops innovative products and services for the prevention, diagnosis, monitoring, screening, and treatment of diseases. Roche Diagnostics Belgium is based in Diegem, Belgium, and was founded in 1958. The private company offers next-generation sequencing products and in vitro diagnostics that are an integral part of decision-making along the entire continuum of a patient's health or disease. The CEO is Thomas Schinecker.	Biotechnology

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

217.3 CHF

Average target price

279.4 CHF

Spread / Average Target

+28.57%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals